LACK OF AN IMPORTANT INFLUENCE OF CYP2D6 OXIDATION STATUS ON THE PHARMACOKINETICS OF MOCLOBEMIDE

被引：0
|
作者：
GUENTERT, TW [1 ]
GRANGE, S [1 ]
BOCK, J [1 ]
WALDBURGER, R [1 ]
BIRNBOECK, H [1 ]
HOFFMANNLAROCHE, F [1 ]
机构：
[1] F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1995年 / 57卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [1] Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
    Brynne, N
    Dalén, P
    Alván, G
    Bertilsson, L
    Gabrielsson, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) : 529 - 539
  • [2] LACK OF ASSOCIATION BETWEEN CYP2D6 GENETIC POLYMORPHISM AND PHARMACOKINETICS OF CLOMIPHENE
    Kim, Y. H.
    Byeon, J. Y.
    Lee, H. J.
    Kim, S. H.
    Lee, Y. S.
    Lee, Y. J.
    Lee, S. Y.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E50 - E50
  • [3] REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9
    GUENTERT, TW
    GRAM, LF
    GRANGE, S
    BROSEN, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 137 - 137
  • [4] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [5] Influence of CYP2D6 phenotype on the Pharmacokinetics-Pharmacodynamics of tramadol
    Percevault, S.
    De La Gastine, B.
    Varin, L.
    Richard, N.
    Loilier, M.
    Bleyzac, N.
    Bourguignon, L.
    Lelong-Boulouard, V.
    Goutelle, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 43 - 44
  • [6] CYP2D6 and chlorpheniramine pharmacokinetics.
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, JW
    Woosley, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P7 - P7
  • [7] Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
    Li, Susie Xiujiang
    Pequignot, Edward
    Panebianco, Deborah
    Lupinacci, Paul
    Majumdar, Anup
    Rosen, Laura
    Ahmed, Tuli
    Royalty, Lane E.
    Rushmore, Thomas H.
    Murphy, M. Gail
    Petty, Kevin J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (07): : 792 - 801
  • [8] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [9] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [10] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
12345